JP2020508042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508042A5 JP2020508042A5 JP2019544016A JP2019544016A JP2020508042A5 JP 2020508042 A5 JP2020508042 A5 JP 2020508042A5 JP 2019544016 A JP2019544016 A JP 2019544016A JP 2019544016 A JP2019544016 A JP 2019544016A JP 2020508042 A5 JP2020508042 A5 JP 2020508042A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition according
- component
- inhibitor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 15
- 239000003446 ligand Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 239000007850 fluorescent dye Substances 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 2
- 239000013522 chelant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 1
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 claims 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 1
- 102000010449 Folate receptor beta Human genes 0.000 claims 1
- 108050001930 Folate receptor beta Proteins 0.000 claims 1
- 102000001267 GSK3 Human genes 0.000 claims 1
- 108060006662 GSK3 Proteins 0.000 claims 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000007721 medicinal effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023047827A JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460118P | 2017-02-17 | 2017-02-17 | |
| US62/460,118 | 2017-02-17 | ||
| PCT/US2018/018557 WO2018152451A1 (en) | 2017-02-17 | 2018-02-17 | Targeted ligand-payload based drug delivery for cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023047827A Division JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508042A JP2020508042A (ja) | 2020-03-19 |
| JP2020508042A5 true JP2020508042A5 (enExample) | 2021-04-01 |
| JP7288402B2 JP7288402B2 (ja) | 2023-06-07 |
Family
ID=63170493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Active JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
| JP2023047827A Pending JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023047827A Pending JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12343403B2 (enExample) |
| EP (2) | EP4600267A3 (enExample) |
| JP (2) | JP7288402B2 (enExample) |
| KR (1) | KR102595249B1 (enExample) |
| CN (2) | CN118634339B (enExample) |
| AU (1) | AU2018221171B2 (enExample) |
| CA (1) | CA3053534A1 (enExample) |
| ES (1) | ES3024357T3 (enExample) |
| WO (1) | WO2018152451A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CN108697798A (zh) | 2016-02-16 | 2018-10-23 | 达纳-法伯癌症研究所有限公司 | 免疫疗法组合物及方法 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3024357T3 (en) * | 2017-02-17 | 2025-06-04 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| CN120154716A (zh) * | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| JP7774961B2 (ja) | 2018-02-06 | 2025-11-25 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| BR112020020887A2 (pt) | 2018-04-12 | 2021-04-06 | Umoja Biopharma, Inc | Vetores virais e linhagens celulares de empacotamento |
| CN112399852A (zh) | 2018-06-28 | 2021-02-23 | 达纳-法伯癌症研究所有限公司 | 固体和液体恶性肿瘤中多重抗原受体t细胞对多种抗原的靶向 |
| EP3833400A4 (en) * | 2018-08-07 | 2022-06-15 | Purdue Research Foundation | REJUVENATION OF CAR-T CELLS |
| WO2020154455A1 (en) * | 2019-01-23 | 2020-07-30 | The Johns Hopkins University | Non-immunosuppressive fk506 analogs and use thereof |
| AR119271A1 (es) | 2019-06-11 | 2021-12-09 | Shire Human Genetic Therapies | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada |
| CA3150095A1 (en) * | 2019-09-06 | 2021-03-11 | Shirley O'dea | IMMUNE CELL ENGINEERING FOR EX VIVO CELLULAR THERAPY APPLICATIONS |
| WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| WO2022044024A1 (en) * | 2020-08-31 | 2022-03-03 | Ramot At Tel-Aviv University Ltd. | Small molecule modulators of gsk-3 activity |
| WO2022130014A1 (en) | 2020-12-16 | 2022-06-23 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| US20240043529A1 (en) * | 2020-12-22 | 2024-02-08 | Eutropics Pharmaceuticals, Inc. | Methods and compositions related to bcl2 and bim heterodimer antibodies |
| CN113462649B (zh) * | 2021-05-27 | 2022-08-23 | 浙江大学 | Mek抑制剂在减少car-t细胞耗竭和终末分化中的应用 |
| JP2024526860A (ja) * | 2021-07-21 | 2024-07-19 | イミュニティバイオ，インコーポレーテッド | 初代ＮＫ細胞内での発現のためのキメラ抗原受容体ｍＲＮＡ分子の生成 |
| CN116041545A (zh) * | 2022-12-12 | 2023-05-02 | 南方医科大学 | 一种靶向荧光素或生物素的通用型car及其应用 |
| WO2024206913A2 (en) * | 2023-03-31 | 2024-10-03 | Northwestern University | Compositions for antigen-specific immune cell activation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| US7547759B2 (en) | 2001-03-09 | 2009-06-16 | Board Of Regents, The University Of Texas System | Induction of tumor immunity by variants of folate binding protein |
| WO2005103250A1 (ja) * | 2004-04-26 | 2005-11-03 | Takami Matsuyama | 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬 |
| WO2011079227A1 (en) * | 2009-12-23 | 2011-06-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| WO2010118169A2 (en) | 2009-04-08 | 2010-10-14 | The Regents Of The University Of California | Human protein scaffold with controlled serum pharmacokinetics |
| US20190054117A1 (en) * | 2014-12-19 | 2019-02-21 | Novartis Ag | Dimerization switches and uses thereof |
| US10683506B2 (en) | 2015-04-10 | 2020-06-16 | The Methodist Hospital System | CD117 ligand-drug conjugates for targeted cancer therapy |
| JP6887685B2 (ja) * | 2015-08-12 | 2021-06-16 | マサチューセッツ インスティテュート オブ テクノロジー | ナノ粒子の細胞表面共役 |
| TW201740958A (zh) * | 2016-01-15 | 2017-12-01 | 依圖比克斯公司 | 用於t細胞免疫療法之方法及組合物 |
| AU2017345479B2 (en) * | 2016-10-19 | 2024-03-21 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| CN110191948A (zh) * | 2016-11-02 | 2019-08-30 | 巴塞尔大学 | 用于细胞疗法的免疫可识别的细胞表面变体 |
| ES3024357T3 (en) | 2017-02-17 | 2025-06-04 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
-
2018
- 2018-02-17 ES ES18754879T patent/ES3024357T3/es active Active
- 2018-02-17 EP EP25163099.2A patent/EP4600267A3/en active Pending
- 2018-02-17 JP JP2019544016A patent/JP7288402B2/ja active Active
- 2018-02-17 CN CN202410423409.8A patent/CN118634339B/zh active Active
- 2018-02-17 EP EP18754879.7A patent/EP3583218B1/en active Active
- 2018-02-17 CN CN201880024308.6A patent/CN110662839A/zh active Pending
- 2018-02-17 AU AU2018221171A patent/AU2018221171B2/en active Active
- 2018-02-17 KR KR1020197026818A patent/KR102595249B1/ko active Active
- 2018-02-17 WO PCT/US2018/018557 patent/WO2018152451A1/en not_active Ceased
- 2018-02-17 US US16/486,632 patent/US12343403B2/en active Active
- 2018-02-17 CA CA3053534A patent/CA3053534A1/en active Pending
-
2023
- 2023-03-24 JP JP2023047827A patent/JP2023082054A/ja active Pending
-
2025
- 2025-04-30 US US19/194,112 patent/US20250262313A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508042A5 (enExample) | ||
| Goldstein et al. | Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging | |
| Ristau et al. | The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research | |
| JP7455510B2 (ja) | 悪性脳腫瘍における標的化粒子の浸透、分布および応答のための組成物及び方法 | |
| Luo et al. | Cholangiocyte endothelin 1 and transforming growth factor β1 production in rat experimental hepatopulmonary syndrome | |
| MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
| Miao et al. | Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein | |
| MA42381B1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
| Kwon et al. | 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents | |
| BRPI0511126A (pt) | métodos de tratamento utilizando proteìnas de ligação de albumina como alvos | |
| Milenic et al. | Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease | |
| Tolmachev et al. | Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels | |
| Roof et al. | Immunotherapy in HPV-related oropharyngeal cancers | |
| JP2010539112A (ja) | 抗腫瘍薬のための分類マーカーとしてのｅｄ‐ｂフィブロネクチン | |
| Osborne et al. | Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment | |
| Ku et al. | MicroSPECT/CT imaging of cell-line and patient-derived EGFR-positive tumor xenografts in mice with panitumumab Fab modified with hexahistidine peptides to enable labeling with 99mTc (I) tricarbonyl complex | |
| Wang et al. | Screening, construction, and preliminary evaluation of CLDN18. 2-specific peptides for noninvasive molecular imaging | |
| Altai et al. | Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine | |
| Peraudeau et al. | Combination of targeted therapies for colorectal cancer treatment | |
| Fottner et al. | In vivo molecular imaging of somatostatin receptors in pancreatic islet cells and neuroendocrine tumors by miniaturized confocal laser-scanning fluorescence microscopy | |
| Ferris et al. | Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma | |
| Sakai et al. | Clinical effect and immunological response in patients with advanced malignant glioma treated with WT1-pulsed dendritic cell-based immunotherapy: A report of two cases | |
| Singh et al. | Utility of PK-PD Modeling and simulation to improve decision making for antibody-drug conjugate development | |
| WO2023159102A1 (en) | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer | |
| Rossfeld et al. | Biological evaluation of a fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model |